Precision oncology with selective RET inhibitor selpercatinib in -rearranged cancers
Rearranged during transfection ( RET ) is a protooncogene that encodes for receptor tyrosine kinase with downstream effects on multiple cellular pathways. Activating RET alterations can occur and lead to uncontrolled cellular proliferation as a hallmark of cancer development. Oncogenic RET fusions a...
Main Authors: | Mohamed A. Gouda, Vivek Subbiah |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-06-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359231177015 |
Similar Items
-
Assessing the Effectiveness of Selective RET Inhibitors in RET-Positive Cancers through Fluorodeoxyglucose Uptake Analysis
by: Kalevi Kairemo, et al.
Published: (2024-08-01) -
Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
by: Jun Sakakibara-Konishi, et al.
Published: (2025-01-01) -
Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)
by: Rachel E. Reingold, MD, et al.
Published: (2025-03-01) -
Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
by: Tomoya Yokota
Published: (2022-09-01) -
The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib
by: Tao Shen, et al.
Published: (2021-06-01)